Rezolute (NASDAQ:RZLT) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Posted by Jeff Wilder on Nov 6th, 2026

Rezolute (NASDAQ:RZLT – Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.01, FiscalAI reports.

Rezolute Stock Performance

RZLT stock traded up $0.24 during midday trading on Friday, hitting $3.88. The company’s stock had a trading volume of 1,520,129 shares, compared to its average volume of 1,445,984. The firm’s 50-day moving average is $4.14 and its 200-day moving average is $3.91. Rezolute has a 12 month low of $1.07 and a 12 month high of $11.46.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. Citigroup reiterated a “market outperform” rating on shares of Rezolute in a research note on Thursday, October 15th. Lake Street Capital increased their target price on Rezolute from $9.00 to $12.00 and gave the stock a “buy” rating in a research note on Tuesday, October 6th. Cantor Fitzgerald upgraded Rezolute from a “neutral” rating to an “overweight” rating in a report on Monday, October 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Rezolute in a research report on Thursday, October 15th. Finally, Citizens Jmp upped their price target on shares of Rezolute from $11.00 to $15.00 and gave the stock a “market outperform” rating in a research note on Tuesday, October 6th. Twelve research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $11.22.

Check Out Our Latest Research Report on Rezolute

Rezolute Company Profile

(Get Free Report)

Rezolute, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic diseases involving abnormal insulin activity. The company’s lead product candidate is RZ358, also known as ersodetug, an investigational monoclonal antibody designed to reduce the effects of excessive insulin by binding to an allosteric site on the insulin receptor.

RZ358 is being developed primarily for the treatment of congenital hyperinsulinism, a rare disorder in which the pancreas releases too much insulin, causing potentially severe and recurrent hypoglycemia.